Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
ExoCoBio is the 4th largest funded exosome startup in the world
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business.
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top-tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, and Platinum Technology Investment.
Since it was established in January 2017, ExoCoBio has raised about $46 million accumulatively, including a series A round in April 2017 of $11 million.
Series B money will be used to set up GMP-compliant exosome manufacturing facilities to produce exosome pharmaceuticals, to attract high-quality talents, and to secure additional business opportunities for commercialization in the cosmetics industry.
Source: 2018.9.26